Edition:
United States

China Resources Double-Crane Pharmaceutical Co Ltd (600062.SS)

600062.SS on Shanghai Stock Exchange

21.04CNY
29 Aug 2016
Change (% chg)

¥-0.29 (-1.36%)
Prev Close
¥21.33
Open
¥21.25
Day's High
¥21.36
Day's Low
¥20.85
Volume
6,326,510
Avg. Vol
6,256,437
52-wk High
¥24.84
52-wk Low
¥15.50

600062.SS

Chart for 600062.SS

About

CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in manufacture, processing and distribution of pharmaceuticals. The Company's products are classified into three categories: infusion solutions, including glucose injections, fructose injections and levofloxacin lactate and sodium... (more)

Overall

Beta: 0.74
Market Cap(Mil.): ¥15,452.96
Shares Outstanding(Mil.): 724.47
Dividend: 0.19
Yield (%): 0.87

Financials

  600062.SS Industry Sector
P/E (TTM): 19.59 36.93 36.63
EPS (TTM): 1.09 -- --
ROI: 12.22 14.69 14.12
ROE: 12.29 15.48 15.04

BRIEF-China Resources Double-crane Pharmaceutical unit gets GMP certificate

Aug 25 China Resources Double-crane Pharmaceutical Co., Ltd. :

Aug 24 2016

BRIEF-China Resources Double-crane Pharmaceutical gets GMP certificate

Aug 25 China Resources Double-crane Pharmaceutical Co., Ltd :

Aug 24 2016

BRIEF-China Resources Double-crane Pharmaceutical unit gets nod for clinic trial

Aug 10 China Resources Double-crane Pharmaceutical Co., Ltd. :

Aug 09 2016

BRIEF-China Resources Double-crane Pharmaceutical gets nod for clinic trial

July 26 China Resources Double-crane Pharmaceutical Co., Ltd. :

Jul 25 2016

BRIEF-China Resources Double-Crane Pharmaceutical to pay 2015 div on July 20

July 13 China Resources Double-Crane Pharmaceutical Co., Ltd.:

Jul 13 2016

BRIEF-China Resources Double-crane Pharmaceutical gets nod for clinic trial

June 1 China Resources Double-crane Pharmaceutical Co., Ltd. :

Jun 01 2016

BRIEF-China Resources Double-Crane Pharmaceutical receives drug clinical trial permission

May 24 China Resources Double-Crane Pharmaceutical Co., Ltd.:

May 24 2016

BRIEF-China Resources Double-Crane Pharma's 2015 net profit down 10.3 pct

March 10 China Resources Double-Crane Pharmaceutical Co Ltd

Mar 10 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : Sadif Analytics Prime
$25.00
Provider : Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.